A cross-sectional study of incident pre- and post-menopausal breast cancer patients reported a less diverse microbiome and differential abundance of Firmicutes in women with human epidermal growth factor receptor 2 (HER2) positive breast cancer compared to HER2 negative breast cancer (Wu et al., 2020). This evidence concerns the gene ERBB2 and breast carcinoma.